>>>Part-1
>>>Part-2
43.1 Choose the most potent and most efficacious LDLcholesterol
lowering HMG-CoA reductase inhibitor:
A. Lovastatin
B. Simvastatin
C. Pravastatin
D. Atorvastatin
43.2 The following is true of simvastatin except:
A. It is more potent than lovastatin
B. At the highest recommended dose, it causes greater LDL-cholesterol lowering than
lovastatin
C. It does not undergo first pass metabolism in liver
D. It can raise HDL-cholesterol level when the same is low at base line
43.3 Select the most appropriate hypolipidemic drug for a patient with raised LDL-cholesterol level but normal triglyceride level:
A. A HMG-CoA reductase inhibitor
B. A fibric acid derivative
C. Gugulipid
D. Nicotinic acid
43.4 Select the drug which reduces cholesterol synthesis
in liver, increases expression of LDL receptors on
hepatocytes and has been found to reduce mortality
due to coronary artery disease:
A. Simvastatin
B. Nicotinic acid
C. Gemfibrozil
D. Colestipol
43.5 The rare but characteristic adverse effect of HMGCoA
reductase inhibitors is:
A. Onycolysis
B. Myopathy
C. Alopecia
D. Oculomucocutaneous syndrome
43.6 Features of atorvastatin include the following:
A. Dose to dose most potent HMG-CoA reductase inhibitor
B. Higher ceiling of LDL-cholesterol lowering
action than lovastatin
C. Antioxidant property
D. All of the above
43.7 Select the hypocholesterolemic drug which interferes
with intestinal absorption of bile salts and cholesterol,
and secondarily increases cholesterol turnover in the liver:
A. Gemfibrozil
B. Cholestyramine
C. Lovastatin
D. Bezafibrate
43.8 Gemfibrozil has the following features except:
A. It lowers plasma LDL cholesterol to a greater extent than triglycerides
B. It tends to raise plasma HDL-cholesterol level
C. It is a first line drug for type III, type IV and type V hyperlipoproteinemia
D. It reduces the incidence of myocardial infarction
43.9 Antiatherosclerotic effect of which class of hypolipidemic
drugs may involve additional mechanisms
like improved endothelial function, reduced LDL
oxidation and antiinflammatory property:
A. Bile acid sequestrant resins
B. Statins
C. Fibrates
D. Nicotinic acid
43.10 Select the hypolipidemic drug that enhances
lipoprotein synthesis, fatty acid oxidation and LDLreceptor
expression in liver through paroxisome
proliferator-activated receptor α:
A. Lovastatin
B. Atorvastatin
C. Bezafibrate
D. Nicotinic acid
43.11 A patient with coronary artery disease has raised
serum triglyceride level (500 mg/dl) but normal total
cholesterol level (150 mg/dl). Which hypolipidemic
drug should be prescribed:
A. Probucol
B. Gemfibrozil
C. Cholestyramine
D. Lovastatin
43.12 The following is true of bezafibrate except:
A. It activates lipoprotein lipase
B. It mainly lowers serum triglyceride level with
smaller effect on LDL cholesterol level
C. It increases the incidence of myopathy due to statins
D. It tends to lower plasma fibrinogen level
43.13 Choose the correct statement about lovastatin:
A. It markedly lowers plasma triglyceride with little effect on cholesterol level
B. It is used as an adjuvant to gemfibrozil for type III hyperlipoproteinemia
C. It is not effective in diabetes associated hypercholesterolemia
D. It is a competitive inhibitor of the rate limiting step in cholesterol synthesis
43.14 Which of the following hypolipidemic drugs is most
effective in raising HDL-cholesterol level and lowers
serum triglycerides:
A. Nicotinic acid
B. Fenofibrate
C. Cholestyramine
D. Pravastatin
43.`15 What is true of nicotinic acid as well as nicotinamide:
A. Both possess vitamin B3 activity
B. Both cause cutaneous vasodilatation
C. Both lower plasma triglyceride and VLDL levels
D. Both cause hyperglycaemia after prolonged medication
43.16 Pretreatment with the following drug can be employed
to reduce intolerable flushing, warmth and itching
caused by nicotinic acid when used for lowering
plasma lipids:
A. Chlorpheniramine
B. Atropine
C. Aspirin
D. Prednisolone
43.17 Which hypolipidemic drug has been used to control
and prevent pancreatitis in familial hypertriglyceridemia:
A. Lovastatin
B. Nicotinic acid
C. Cholestyramine
D. Clofibrate
43.18 Select the first line hypolipidemic drug/drugs for
treating hypertriglyceridemia in a subject with normal
cholesterol level:
A. Fibrates
B. HMG-CoA reductase inhibitors
C. Nicotinic acid
D. Both 'A' and 'C' are correct
43.19 Specific drug therapy to lower serum triglycerides
(TG) in a subject with normal LDL-cholesterol level is indicated:
A. In all subjects with serum TG> 150 mg/dl
B. In subjects with existing coronary artery disease and serum TG > 150 mg/dl
C. In subjects with HDL-cholesterol < 40 mg/dl and serum TG > 150 mg/dl
D. Both 'B' and 'C' are correct
43.20 In a 50-year-old male without any other coronary
artery disease risk factor, hypocholesterolemic drugs
are considered necessary when the serum LDLcholesterol
level is higher than:
A. 130 mg/dl
B. 160 mg/dl
C. 190 mg/dl
D. 240 mg/dl
43.21 High molecular weight, pharmacodynamically inert,
nonantigenic substances which form colloidal solution are used as:
A. Osmotic purgatives
B. Osmotic diuretics
C. Plasma expanders
D. All of the above
43.22 As a plasma expander, dextran has the following advantages except:
A. It exerts oncotic pressure similar to plasma proteins
B. It keeps plasma volume expanded for about 24 hours
C. It is nonpyrogenic
D. It does not interfere with grouping and cross matching of blood
43.23 Hydroxyethyl starch is a:
A. Plasma expander
B. Haemostatic
C. Heparin substitute
D. Bile acid sequestrant
43.24 Plasma expanders are used in the following conditions except:
A. Congestive heart failure
B. Extensive burns
C. Mutilating injuries
D. Endotoxin shock
Ans:
43.1 D 43.2 C 43.3 A 43.4 A 43.5 B 43.6D 43.7 B 43.8 A 43.9 B 43.10 C 43.11 B 43.12 C 43.13D 43.14 A 43.15 A 43.16 C 43.17 B 43.18D 43.19D 43.20 C 43.21 C 43.22D 43.23 A 43.24 A
Thank you for sharing knowledge
ReplyDeleteE-pharmacy market in India